In focus · trending topic

Neos

13 stories · following the connections

Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

By Nasdaq OMXJun 20, 2017, 1:47 AM UTC

Neos Therapeutics to Present at 2017 UBS Global Healthcare Conference

By Nasdaq OMXMay 16, 2017, 11:31 AM UTC

Neos Therapeutics to Present at 2017 UBS Global Healthcare Conference

By Nasdaq OMXMay 16, 2017, 11:31 AM UTC

Neos Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

By Nasdaq OMXMar 14, 2017, 11:00 AM UTC

Neos Therapeutics to Host Fourth Quarter and Year-End 2016 Financial Results Conference Call on March 14, 2017

By Nasdaq OMXMar 8, 2017, 12:30 PM UTC

Neos Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

By Nasdaq OMXFeb 28, 2017, 12:30 PM UTC

Neos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference

By Nasdaq OMXFeb 16, 2017, 12:30 PM UTC

Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD

By Nasdaq OMXDec 20, 2016, 12:30 PM UTC